Formycon AG – LSE:0W4N.L
Formycon AG stock price today
Formycon AG stock price monthly change
Formycon AG stock price quarterly change
Formycon AG stock price yearly change
Formycon AG key metrics
Market Cap | 923.84M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 8.32 |
Revenue | 120.19M |
EBITDA | -14.40M |
Income | 111.78M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -11.99% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFormycon AG stock price history
Formycon AG stock forecast
Formycon AG financial statements
| Jun 2022 | 17.64M | 80.03M | 453.59% |
|---|---|---|---|
| Dec 2022 | 24.85M | -44.03M | -177.2% |
| Jun 2023 | 43.78M | 1.80M | 4.12% |
| Dec 2023 | 33.90M | 73.99M | 218.22% |
| 2025 | 87.89M | 3.25M | 3.71% |
|---|---|---|---|
| 2026 | 193.16M | 77.03M | 39.88% |
| 2027 | 209.05M | 88.85M | 42.5% |
| 2028 | 221.24M | 62.10M | 28.07% |
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 853697000 | 497.11M | 58.23% |
|---|---|---|---|
| Dec 2022 | 853697000 | 497.11M | 58.23% |
| Jun 2023 | 912944000 | 485.52M | 53.18% |
| Dec 2023 | 890362000 | 387.61M | 43.53% |
| Jun 2022 | -10.20M | -6.13M | 9.55M |
|---|---|---|---|
| Dec 2022 | -8.78M | -30.93M | 31.29M |
| Jun 2023 | -8.09M | -12.56M | 47.70M |
| Dec 2023 | -1.30M | -5.33M | -3.19M |
Formycon AG alternative data
| Aug 2023 | 137 |
|---|---|
| Sep 2023 | 137 |
| Oct 2023 | 224 |
| Nov 2023 | 224 |
| Dec 2023 | 224 |
| Jan 2024 | 224 |
| Feb 2024 | 224 |
| Mar 2024 | 224 |
| Apr 2024 | 224 |
| May 2024 | 224 |
| Jun 2024 | 238 |
| Jul 2024 | 238 |
Formycon AG other data
| Patent |
|---|
Application Filling date: 14 May 2020 Issue date: 30 Jun 2022 |
Application Filling date: 26 Feb 2022 Issue date: 9 Jun 2022 |
Application Filling date: 21 May 2021 Issue date: 25 Nov 2021 |
Application Filling date: 21 Jan 2021 Issue date: 22 Jul 2021 |
Grant Filling date: 18 Nov 2016 Issue date: 23 Feb 2021 |
Application Filling date: 13 Aug 2020 Issue date: 14 Jan 2021 |
Application Filling date: 14 Jan 2020 Issue date: 30 Jul 2020 |
Application STERILIZABLE PRE-FILLED PHARMACEUTICAL PACKAGES COMPRISING A LIQUID FORMULATION OF A VEGF-ANTAGONIST Filling date: 24 May 2018 Issue date: 30 Jul 2020 |
Grant Filling date: 26 Jan 2017 Issue date: 3 Mar 2020 |
Grant Filling date: 13 Nov 2014 Issue date: 25 Feb 2020 |
| Insider | Compensation |
|---|---|
Dr. Carsten Brockmeyer Ph.D. Chief Executive Officer & Member of Executive Board | |
Dr. Friedrich-Wilhelm Steinweg Co-Founder | |
Dr. Nicolas Combé Ph.D. Co-Founder, Chief Financial Officer & Member of Executive Board | |
Dr. Stefan Glombitza Chief Operating Officer & Member of Executive Board |
-
What's the price of Formycon AG stock today?
One share of Formycon AG stock can currently be purchased for approximately $37.2.
-
When is Formycon AG's next earnings date?
Unfortunately, Formycon AG's (0W4N.L) next earnings date is currently unknown.
-
Does Formycon AG pay dividends?
No, Formycon AG does not pay dividends.
-
How much money does Formycon AG make?
Formycon AG has a market capitalization of 923.84M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 82.83% to 77.7M US dollars.
-
What is Formycon AG's stock symbol?
Formycon AG is traded on the LSE under the ticker symbol "0W4N.L".
-
What is Formycon AG's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Formycon AG?
Shares of Formycon AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Formycon AG's key executives?
Formycon AG's management team includes the following people:
- Dr. Carsten Brockmeyer Ph.D. Chief Executive Officer & Member of Executive Board
- Dr. Friedrich-Wilhelm Steinweg Co-Founder
- Dr. Nicolas Combé Ph.D. Co-Founder, Chief Financial Officer & Member of Executive Board
- Dr. Stefan Glombitza Chief Operating Officer & Member of Executive Board
-
Is Formycon AG founder-led company?
Yes, Formycon AG is a company led by its founders Dr. Friedrich-Wilhelm Steinweg and Dr. Nicolas Combé Ph.D..
-
How many employees does Formycon AG have?
As Jul 2024, Formycon AG employs 238 workers, which is 6% more then previous quarter.
-
When Formycon AG went public?
Formycon AG is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Formycon AG's official website?
The official website for Formycon AG is formycon.com.
Formycon AG company profile:
Formycon AG
formycon.comLSE
239
Medical - Pharmaceuticals
Healthcare
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Planegg, 82152
:
ISIN: DE000A1EWVY8
:
